{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T18:10:11Z","timestamp":1794593411895,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["320030-227432"],"award-info":[{"award-number":["320030-227432"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["883582-ECOEVODRTB"],"award-info":[{"award-number":["883582-ECOEVODRTB"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis (TB) remains a major public health concern. Improving TB control programs and treatment success requires a deeper understanding of the factors that determine disease presentation and treatment outcomes. While the importance of patient factors is well established, our understanding of the bacterial determinants of disease presentation and treatment outcomes in TB remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, we analyzed the\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      complex (MTBC) genomes and the associated clinical data from 4529\u00a0TB patients in the country of Georgia covering a period of 13\u00a0years. We used multivariable modeling together with genome-wide association studies (GWAS) to identify patient and bacterial factors that determine TB disease manifestation and clinical outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Multivariable modelling confirmed the role of demographic and clinical factors in determining treatment outcomes, as well as the efficacy of novel TB treatments containing bedaquiline. In addition, we found that several bacterial factors, including the MTBC lineage, the specific mutations conferring resistance to rifampicin and fluoroquinolones, as well as a high bacterial burden, were associated with unfavorable outcomes. GWAS analyses revealed no bacterial genetic mutations associated with treatment outcomes beyond the known drug resistance-conferring mutations. However, we found that mutations in the bacterial gene\n                      <jats:italic>sufD<\/jats:italic>\n                      were linked to a reduced risk of lung cavities and a lower bacterial burden within patients. By contrast, specific mutations conferring resistance to rifampicin and fitness compensatory mutations were associated with a higher bacterial burden.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our results show that both patient and bacterial factors determine disease presentation and clinical outcomes in TB. They also support the rationale of optimizing treatment regimens against drug-resistant TB with existing drugs based on the specific genetic features of the pathogen. Finally, our results highlight\n                      <jats:italic>sufD<\/jats:italic>\n                      as a possible therapeutic candidate.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-025-01555-0","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:19:54Z","timestamp":1763137194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical and bacterial determinants of unfavorable tuberculosis treatment outcomes: an observational study in Georgia"],"prefix":"10.1186","volume":"17","author":[{"given":"Galo A.","family":"Goig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Maghradze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kakha","family":"Mchedlishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teona","family":"Avaliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Tsutsunava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Brites","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevda","family":"Kalkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Borrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rusudan","family":"Aspindzelashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaza","family":"Avaliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Kipiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestani","family":"Tukvadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levan","family":"Jugheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Gagneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"1555_CR1","unstructured":"Global tuberculosis report 2024. Geneva: World Health Organization; 2024."},{"key":"1555_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jinf.2023.06.014","volume":"87","author":"OS Pedersen","year":"2023","unstructured":"Pedersen OS, Holmgaard FB, Mikkelsen MKD, Lange C, Sotgiu G, Lillebaek T, et al. Global treatment outcomes of extensively drug-resistant tuberculosis in adults: a systematic review and meta-analysis. J Infect. 2023;87:177\u201389.","journal-title":"J Infect"},{"key":"1555_CR3","doi-asserted-by":"crossref","unstructured":"Rehman OU, Fatima E, Ali Abraish, Akram U, Nashwan A, Yunus F. Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis. J Clin Tuberc Other Mycobact Dis. 2024;34:100405.","DOI":"10.1016\/j.jctube.2023.100405"},{"key":"1555_CR4","doi-asserted-by":"crossref","unstructured":"Goig GA, Loiseau C, Maghradze N, Mchedlishvili K, Avaliani T, Brites D, et al. Transmission as a Key Driver of Resistance to the New Tuberculosis Drugs. N Engl J Med. 2025; Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMc2404644.","DOI":"10.1101\/2024.06.28.24309543"},{"key":"1555_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044687","volume":"11","author":"LS Peetluk","year":"2021","unstructured":"Peetluk LS, Ridolfi FM, Rebeiro PF, Liu D, Rolla VC, Sterling TR. Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults. BMJ Open. 2021;11:e044687.","journal-title":"BMJ Open"},{"key":"1555_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-44325-5","volume":"15","author":"The CRyPTIC Consortium","year":"2024","unstructured":"The CRyPTIC Consortium. Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach. Nat Commun. 2024;15:1\u201313.","journal-title":"Nat Commun"},{"key":"1555_CR7","doi-asserted-by":"publisher","first-page":"e570","DOI":"10.1016\/S2666-5247(24)00022-3","volume":"5","author":"S Stanley","year":"2024","unstructured":"Stanley S, Spaulding CN, Liu Q, Chase MR, Ha DTM, Thai PVK, et al. Identification of bacterial determinants of tuberculosis infection and treatment outcomes: a phenogenomic analysis of clinical strains. Lancet Microbe. 2024;5:e570\u201380.","journal-title":"Lancet Microbe"},{"key":"1555_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00070-24","volume":"12","author":"P Rupasinghe","year":"2024","unstructured":"Rupasinghe P, Reenaers R, Vereecken J, Mulders W, Cogneau S, Merker M, et al. Refined understanding of the impact of the complex diversity on the intrinsic susceptibility to pretomanid. Microbiol Spectr. 2024;12:e0007024.","journal-title":"Microbiol Spectr"},{"key":"1555_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/jac\/dkv360","volume":"71","author":"L Rigouts","year":"2016","unstructured":"Rigouts L, Coeck N, Gumusboga M, de Rijk WB, Aung KJM, Hossain MA, et al. Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. J Antimicrob Chemother. 2016;71:314\u201323.","journal-title":"J Antimicrob Chemother"},{"key":"1555_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4103\/ijmy.ijmy_116_23","volume":"12","author":"R Dixit","year":"2023","unstructured":"Dixit R, Mohan E, Gupta A, Gupta PS, Patni T, Goyal M, et al. Fluoroquinolone resistance mutations among Mycobacterium tuberculosis and their interconnection with treatment outcome. Int J Mycobacteriol. 2023;12:294.","journal-title":"Int J Mycobacteriol"},{"key":"1555_CR11","doi-asserted-by":"crossref","unstructured":"Liu Q, Wang D, Martinez L, Lu P, Lu W, Wang J. Mycobacterium tuberculosis Beijing genotype strains and unfavourable treatment outcomes: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;26:180\u20138.","DOI":"10.1016\/j.cmi.2019.07.016"},{"key":"1555_CR12","doi-asserted-by":"publisher","first-page":"e0001788","DOI":"10.1371\/journal.pgph.0001788","volume":"3","author":"DH Du","year":"2023","unstructured":"Du DH, Geskus RB, Zhao Y, Codecasa LR, Cirillo DM, van Crevel R, et al. The effect of M. tuberculosis lineage on clinical phenotype. PLOS Glob Public Health. 2023;3:e0001788.","journal-title":"PLOS Glob Public Health"},{"key":"1555_CR13","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.chom.2024.10.004","volume":"32","author":"W Worakitchanon","year":"2024","unstructured":"Worakitchanon W, Yanai H, Piboonsiri P, Miyahara R, Nedsuwan S, Imsanguan W, et al. Comprehensive analysis of Mycobacterium tuberculosis genomes reveals genetic variations in bacterial virulence. Cell Host Microbe. 2024;32:1972-87.e6.","journal-title":"Cell Host Microbe"},{"key":"1555_CR14","doi-asserted-by":"crossref","unstructured":"Liu Q, Zhu J, Dulberger CL, Stanley S, Wilson S, Chung ES, et al. Tuberculosis treatment failure associated with evolution of antibiotic resilience. Science. 2022; Available from: https:\/\/www.science.org\/doi\/10.1126\/science.abq2787.","DOI":"10.1126\/science.abq2787"},{"key":"1555_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ijid.2022.10.026","volume":"125","author":"C Genestet","year":"2022","unstructured":"Genestet C, Refr\u00e9gier G, Hodille E, Zein-Eddine R, Le Meur A, Hak F, et al. Mycobacterium tuberculosis genetic features associated with pulmonary tuberculosis severity. Int J Infect Dis. 2022;125:74\u201383.","journal-title":"Int J Infect Dis"},{"key":"1555_CR16","doi-asserted-by":"crossref","unstructured":"Chen Y, Jiang Q, Peierdun M, Takiff HE, Gao Q. The mutational signatures of poor treatment outcomes on the drug-susceptible Mycobacterium tuberculosis genome. 2023; Available from: https:\/\/elifesciences.org\/articles\/84815.","DOI":"10.7554\/eLife.84815.sa2"},{"key":"1555_CR17","unstructured":"Definitions and reporting framework for tuberculosis \u2013 2013 revision: updated December 2014 and January 2020. World Health Organization; 2013. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241505345."},{"key":"1555_CR18","unstructured":"World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance: Second edition. World Health Organization; 2023."},{"key":"1555_CR19","doi-asserted-by":"crossref","unstructured":"Wiatrak M, Weimann A, Dinan A, Brbi\u0107 M, Floto RA. Sequence-based modelling of bacterial genomes enables accurate antibiotic resistance prediction. bioRxiv. 2024. Available from: http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.01.03.574022.","DOI":"10.1101\/2024.01.03.574022"},{"key":"1555_CR20","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/molbev\/msaa015","volume":"37","author":"BQ Minh","year":"2020","unstructured":"Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol Biol Evol. 2020;37:1530\u20134.","journal-title":"Mol Biol Evol"},{"key":"1555_CR21","unstructured":"Goig G, Loiseau C. Clinical and bacterial determinants of unfavorable tuberculosis treatment outcomes: an observational study in Georgia.; Available from: https:\/\/zenodo.org\/records\/17171544."},{"key":"1555_CR22","doi-asserted-by":"crossref","unstructured":"Lees JA, Galardini M, Bentley SD, Weiser JN, Corander J. Pyseer: a comprehensive tool for microbial pangenome-wide association studies. Bioinformatics (Oxford, England). 2018;34. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30535304\/.","DOI":"10.1101\/266312"},{"key":"1555_CR23","first-page":"1974","volume":"218","author":"SS Shin","year":"2018","unstructured":"Shin SS, Modongo C, Baik Y, Allender C, Lemmer D, Colman RE, et al. Mixed Mycobacterium tuberculosis-Strain Infections Are Associated With Poor Treatment Outcomes Among Patients With Newly Diagnosed Tuberculosis, Independent of Pretreatment Heteroresistance. J Infect Dis. 2018;218:1974\u201382.","journal-title":"J Infect Dis"},{"key":"1555_CR24","doi-asserted-by":"crossref","unstructured":"Zetola NM, Shin SS, Tumedi KA, Moeti K, Ncube R, Nicol M, et al. Mixed Mycobacterium tuberculosis Complex Infections and False-Negative Results for Rifampin Resistance by GeneXpert MTB\/RIF Are Associated with Poor Clinical Outcomes. J Clin Microbiol. 2014; Available from: https:\/\/journals.asm.org\/doi\/10.1128\/jcm.02489-13.","DOI":"10.1128\/JCM.02489-13"},{"key":"1555_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2020.104659","volume":"87","author":"M Asare-Baah","year":"2021","unstructured":"Asare-Baah M, S\u00e9raphin MN, Salmon LAT, Lauzardo M. Effect of mixed strain infections on clinical and epidemiological features of tuberculosis in Florida. Infect Genet Evol. 2021;87:104659.","journal-title":"Infect Genet Evol"},{"key":"1555_CR26","doi-asserted-by":"publisher","first-page":"102747","DOI":"10.1016\/j.ebiom.2020.102747","volume":"55","author":"C Nimmo","year":"2020","unstructured":"Nimmo C, Brien K, Millard J, Grant AD, Padayatchi N, Pym AS, et al. Dynamics of within-host Mycobacterium tuberculosis diversity and heteroresistance during treatment. EBioMedicine. 2020;55:102747.","journal-title":"EBioMedicine"},{"key":"1555_CR27","doi-asserted-by":"crossref","unstructured":"Crowder R, Kato-Maeda M, Schwem B, Dela TA, Geocaniga-Gaviola DM, Lopez E, et al. Impact of heteroresistance on treatment outcomes of people with drug-resistant TB. IJTLD Open. 2024;1. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39398438\/.","DOI":"10.5588\/ijtldopen.24.0343"},{"key":"1555_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102857","volume":"77","author":"KA Haigh","year":"2024","unstructured":"Haigh KA, Twabi HH, Boloko L, Namale PE, Lutje V, Nevitt S, et al. Efficacy and safety of higher dose rifampicin in adults with presumed drug-susceptible tuberculosis: an updated systematic review and meta-analysis. EClinicalMedicine. 2024;77:102857.","journal-title":"EClinicalMedicine"},{"key":"1555_CR29","doi-asserted-by":"crossref","unstructured":"Zhou M, Liu AM, Yang XB, Guan CP, Zhang YA, Wang MS, et al. The efficacy and safety of high-dose isoniazid-containing therapy for multidrug-resistant tuberculosis: a systematic review and meta-analysis. Front Pharmacol. 2024;14. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38259285\/.","DOI":"10.3389\/fphar.2023.1331371"},{"key":"1555_CR30","doi-asserted-by":"crossref","unstructured":"Saber MM, Shapiro BJ. Benchmarking bacterial genome-wide association study methods using simulated genomes and phenotypes. Microb Genom. 2020;6. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32100713\/.","DOI":"10.1099\/mgen.0.000337"},{"key":"1555_CR31","doi-asserted-by":"crossref","unstructured":"Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJM. The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis. Science. 2006; Available from: https:\/\/www.science.org\/doi\/10.1126\/science.1124410.","DOI":"10.1126\/science.1124410"},{"key":"1555_CR32","doi-asserted-by":"crossref","unstructured":"Goig GA, Menardo F, Salaam-Dreyer Z, Dippenaar A, Streicher EM, Daniels J, et al. Effect of compensatory evolution in the emergence and transmission of rifampicin-resistant Mycobacterium tuberculosis in Cape Town, South Africa: a genomic epidemiology study. Lancet Microbe. 2023;4. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37295446\/.","DOI":"10.1016\/S2666-5247(23)00110-6"},{"key":"1555_CR33","doi-asserted-by":"publisher","unstructured":"DeJesus MA, Gerrick ER, Xu W, Park SW, Long JE, Boutte CC, et al. Comprehensive essentiality analysis of the Mycobacterium tuberculosis genome via saturating transposon mutagenesis. mBio. 2017;8. Available from: https:\/\/doi.org\/10.1128\/mBio.02133-16.","DOI":"10.1128\/mBio.02133-16"},{"key":"1555_CR34","doi-asserted-by":"crossref","unstructured":"Roberts CA, Al-Tameemi HM, Mashruwala AA, Rosario-Cruz Z, Chauhan U, Sause WE, et al. The Suf Iron-Sulfur Cluster Biosynthetic System Is Essential in Staphylococcus aureus, and Decreased Suf Function Results in Global Metabolic Defects and Reduced Survival in Human Neutrophils. Infect Immun. 2017; Available from:\u00a0https:\/\/journals.asm.org\/doi\/10.1128\/iai.00100-17.","DOI":"10.1128\/IAI.00100-17"},{"key":"1555_CR35","doi-asserted-by":"crossref","unstructured":"Ezraty B, Barras F. The \u201cliaisons dangereuses\u201d between iron and antibiotics. FEMS Microbiol Rev. 2016;40. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26945776\/.","DOI":"10.1093\/femsre\/fuw004"},{"key":"1555_CR36","doi-asserted-by":"publisher","first-page":"723667","DOI":"10.3389\/fmed.2021.723667","volume":"8","author":"AD Giddey","year":"2021","unstructured":"Giddey AD, Ganief TA, Ganief N, Koch A, Warner DF, Soares NC, et al. Cell Wall Proteomics Reveal Phenotypic Adaption of Drug-Resistant Mycobacterium smegmatis to Subinhibitory Rifampicin Exposure. Front Med. 2021;8:723667.","journal-title":"Front Med."},{"key":"1555_CR37","doi-asserted-by":"publisher","first-page":"e00109","DOI":"10.1128\/JB.00109-21","volume":"203","author":"H Cho","year":"2021","unstructured":"Cho H, Misra R. Mutational Activation of Antibiotic-Resistant Mechanisms in the Absence of Major Drug Efflux Systems of Escherichia coli. J Bacteriol. 2021;203:e00109-e121.","journal-title":"J Bacteriol"},{"key":"1555_CR38","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/molbev\/msz086","volume":"36","author":"YT Tamer","year":"2019","unstructured":"Tamer YT, Gaszek IK, Abdizadeh H, Batur TA, Reynolds KA, Atilgan AR, et al. High-order epistasis in catalytic power of Dihydrofolate Reductase gives rise to a rugged fitness landscape in the presence of Trimethoprim selection. Mol Biol Evol. 2019;36:1533\u201350.","journal-title":"Mol Biol Evol"},{"key":"1555_CR39","doi-asserted-by":"publisher","first-page":"1369645","DOI":"10.3389\/fmicb.2024.1369645","volume":"15","author":"N Gorityala","year":"2024","unstructured":"Gorityala N, Baidya AS, Sagurthi SR. Genome mining of Mycobacterium tuberculosis: targeting SufD as a novel drug candidate through in silico characterization and inhibitor screening. Front Microbiol. 2024;15:1369645.","journal-title":"Front Microbiol"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01555-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-025-01555-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01555-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:19:56Z","timestamp":1763137196000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-025-01555-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1555"],"URL":"https:\/\/doi.org\/10.1186\/s13073-025-01555-0","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}